SCHEMBL1890250

SCHEMBL1890250

O=[N+]([O-])c1ccc(Nc2nc(-c3ccncc3)cs2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.64
▸ RAB9A P51151 7/20 0.64
▸ NPC1 O15118 5/20 0.64
▸ MEN1 O00255 4/20 0.64
▸ KMT2A Q03164 4/20 0.64
▸ SMN1; SMN2 Q16637 3/20 0.64
▸ VCP P55072 2/20 0.64
▸ TDP1 Q9NUW8 2/20 0.64
▸ ESR1 P03372 1/20 0.64
▸ POLB P06746 1/20 0.64
▸ ALDH1A1 P00352 3/20 0.63
▸ GAA P10253 3/20 0.63
▸ LMNA P02545 3/20 0.63
▸ HTT P42858 1/20 0.63
▸ NPSR1 Q6W5P4 1/20 0.63
▸ CSNK2A1 P68400 2/20 0.60
▸ ROCK1 Q13464 1/20 0.60
▸ PKM P14618 1/20 0.56
▸ MAPK1 P28482 2/20 0.56
▸ CLK1 P49759 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20379531 0.87 MAPT (0.66) MAPTRAB9ANPC1MEN1KMT2A
SCHEMBL7115032 0.86 ALOX5 (0.68) MAPTRAB9ANPC1MEN1KMT2A
SCHEMBL31126444 0.86 ALOX5 (0.68) MAPTRAB9ANPC1MEN1KMT2A
SCHEMBL1882373 0.85 CSNK2A1 (0.72) MAPTRAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL28716340 0.81 CYP1A1 (0.67) VCPPKM
SCHEMBL1889024 0.79 MAPT (1.00) MAPTRAB9ANPC1MEN1KMT2A
SCHEMBL12639816 0.79 MAPT (0.97) MAPTRAB9ANPC1MEN1KMT2A
SCHEMBL12297166 0.79 MAPT (0.73) MAPTRAB9ANPC1MEN1KMT2A
SCHEMBL1882991 0.79 VCP (1.00) MAPTRAB9ANPC1MEN1KMT2A
SCHEMBL1887335 0.79 ESR1 (1.00) MAPTRAB9ANPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110105436-A1 HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT AUCKLAND UNISERVICES LIMITED (NZ) 2011-05-05 — — US claimed
US-20110105436-A1 HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT AUCKLAND UNISERVICES LIMITED (NZ) 2011-05-05 — — US disclosed
US-20110105436-A1 HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT AUCKLAND UNISERVICES LIMITED (NZ) 2011-05-05 — — US disclosed
US-20110105436-A1 HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT AUCKLAND UNISERVICES LIMITED (NZ) 2011-05-05 — — US disclosed
WO-2009114552-A1 HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2009-09-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105436-A1 HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT VHL, TP53, BECN1 MAPT 2506/4885RAB9A 508/4885NPC1 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback